Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant766 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,477 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00005807 | Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer(BMS-247550) | completed | Phase 1 | 40 | Albert Einstein College of MedicineOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00662233 | Combination Chemotherapy in Treating Patients With Sarcoma | completed | Early Phase 1 | 28 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00410553 | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00030706 | Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | — | Montefiore Medical CenterOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT00484432 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer | completed | Phase 2 | 37 | AGC Biologics S.p.A.INDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT01358071 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer(NGR018) | completed | Phase 2 | 119 | AGC Biologics S.p.A.INDUSTRY | 2 | Sep 27, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT01863693 | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1) | completed | — | 300 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01544049 | Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study | completed | — | 24 | University of WashingtonOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT02046421 | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 31 | University of ChicagoOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT00856180 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT00426257 | Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer | completed | Phase 3 | 242 | The Netherlands Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02107950 | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | completed | Phase 2 | 71 | SOTIO a.s.INDUSTRY | 3 | Aug 15, 2018 | clinicaltrials |
| NCT00230542 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 2 | 44 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00002943 | Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00383279 | Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer | completed | N/A | 70 | Wake Forest University Health SciencesOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00494442 | Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer(ICEBERG 2) | completed | Phase 2 | 58 | AstraZenecaINDUSTRY | 5 | Aug 1, 2018 | clinicaltrials |
| NCT01037751 | M. D. Anderson Symptom Inventory - Ovarian Cancer | completed | — | 158 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00268918 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00520013 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00525460 | Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function | completed | — | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00114166 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 81 | Gynecologic Oncology GroupNETWORK | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00699907 | Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer | completed | Phase 2 | 127 | University of ArizonaOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00867503 | Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer | completed | Phase 2 | 10 | University of ArizonaOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00459290 | Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00569673 | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 71 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01824615 | Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | completed | Phase 2 | 30 | Cathay General HospitalOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01126346 | Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)(HOPE) | completed | N/A | 10 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01652079 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | completed | Phase 2 | 63 | Massachusetts General HospitalOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02948075 | Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | completed | Phase 2 | 31 | NewVac LLCINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02146313 | A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | completed | Phase 1 | 35 | Genentech, Inc.INDUSTRY | 1 | Jun 21, 2018 | clinicaltrials |
| NCT00228319 | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants | completed | Phase 1 / Phase 2 | 27 | Jeanne Drisko, MD, CNS, FACNOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01867086 | Salvage Ovarian FANG™ Vaccine + Carboplatinum | completed | Phase 2 | 1 | Gradalis, Inc.INDUSTRY | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01223235 | Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab | completed | N/A | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT02340611 | A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | completed | Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01132014 | Autologous OC-DC Vaccine in Ovarian Cancer | completed | Early Phase 1 | 67 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | completed | Phase 2 | 168 | AbbVie (prior sponsor, Abbott)INDUSTRY | 8 | Jun 6, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02000778 | EC17 for Intraoperative Imaging in Occult Ovarian Cancer | completed | Phase 1 | 10 | University of PennsylvaniaOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01295489 | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | — | 39 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Oct 9, 2018source: clinicaltrials